Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
Company profile
Website
CEO
Natalie C. Holles
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Latest filings (excl ownership)
15-12B
Securities registration termination
27 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
POSASR
Automatic shelf registration (post-effective amendment)
15 Jan 20
POS AM
Prospectus update (post-effective amendment)
15 Jan 20
POS AM
Prospectus update (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jan 20
Latest ownership filings
3
Taysha Gene Therapies, Inc.
31 Oct 22
SC 13D
Taysha Gene Therapies, Inc.
31 Oct 22
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Audentes Therapeutics, Inc.
11 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
4
Thomas P Soloway
15 Jan 20
4
Julie Smith
15 Jan 20
4
Thomas J. Schuetz
15 Jan 20
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|